Patel, Manish R.
Johnson, Melissa
Winer, Ira
Arkenau, Hendrik-Tobias
Cook, Natalie
Samouëlian, Vanessa
Aljumaily, Raid
Kitano, Shigehisa
Duffy, Christine
Ge, Miaomiao
Elgadi, Mabrouk
Siu, Lillian L.
Funding for this research was provided by:
Boehringer Ingelheim
Article History
Received: 17 March 2023
Accepted: 9 February 2024
First Online: 30 March 2024
Declarations
:
: Manish Patel: Leadership, ION Pharma; Honoraria Pfizer, Pharmacyclics, Bayer, Janssen Oncology, Genentech, Adaptive Biotechnologies; Consulting or advisory role, Pharmacyclics/Janssen, Pfizer/EMD Serono; Speakers Bureau, Exellxis, Genentech/Roche, Taiho Pharmaceutical, Celgene; Research funding (paid to institution), Adagene, Accutar Biotech, Acerta Pharma, ADC Therapeutics, Astellas, Agenus, Aileron Therapeutics, Artios, AstraZeneca, BioNTech AG, BioTheryX, Black Diamond Therapeutics, Blueprint Pharmaceuticals, Boehringer Ingelheim, Celgene, Checkpoint Therapeutics, CicloMed, Clovis Oncology, Compugen, Cyteir Therapeutics, Daiichi Sankyo, Lilly, EMD Serono, Evelo Therapeutics, FORMA Therapeutics, Genentech/Roche, Gilead Sciences, GlaxoSmithKline, H3 Biomedicine, Hengrui Therapeutics, Hutchinson MediPharma, Ignyta, IgM Biosciences, Immugen, Incyte, Jacobio, Janssen, Klus Pharma, Kymab, Loxo, LSK Biopartners; Lycera, MabSpace Biosciences, Macrogenics, Merck, Millennium, Mirati Therapeutics, Moderna Therapeutics, NGM Biopharmaceuticals, Novartis, Nurix, Olema, ORIC, Pfizer, Placon, Portola Pharmaceuticals, Prelude Therapeutics, PureTech, Relay Therapeutics, Ribon Therapeutics, Samumed, Seven and Eight Biopharmaceuticals, Silicon Therapeutics, Syndax, Taiho Pharmaceutical, Takeda, TeneoBio, Tesaro, TopAlliance BioSciences Inc., Treadwell Therapeutics, Vigeo, Zymeworkds Melissa Johnson: Consulting fee (paid to institution), Abbvie, Amgen, Astellas, AstraZeneca, Axelia Oncology, Black Diamond, Calithera Biosciences, Checkpoint Therapeutics, CytomX Therapeutics, Daiichi Sankyo, EcoR1, Editas Medicine, Eisai, EMD Serono, G1 Therapeutics, Genentech/Roche, Genmab, Genocea Biosciences, GlaxoSmithKline, Gritstone Oncology, Ideaya Biosciences, iTeos, Janssen, Lilly, Merck, Mirati Therapeutics, Molecular Axiom, Novartis, Oncorus, Regeneron Pharmaceuticals, Ribon Therapeutics, Sanofi-Aventis, Turning Point Therapeutics, VBL Therapeutics; Grants or funds(paid to institution), Abbvie, Acerta, Adaptimmune, Amgen, Apexigen, Arcus Biosciences, Array BioPharma, Artios Pharma, AstraZeneca, Atreca, BeiGene, BerGenBio, BioAtla, Black Diamond, Boehringer Ingelheim, Calithera Biosciences, Carisma Therapeutics, Corvus Pharmaceuticals, Curis, CytomX, Daiichi Sankyo, Dracen Pharmaceuticals, Dynavax, Lilly, Elicio Therapeutics, EMD Serono, EQRx, Erasca, Exelixis, Fate Therapeutics, Genentech/Roche, Genmab, Genocea Biosciences, GlaxoSmithKline, Gritstone Oncology, Guardant Health, Harpoon, Helsinn Healthcare SA, Hengrui Therapeutics, Hutchison MediPharma, IDEAYA Biosciences, IGM Biosciences, Immunocore, Impact, Incyte, Janssen, Kadmon Pharmaceuticals, Kartos Therapeutics, Loxo Oncology, Lycera, Memorial Sloan-Kettering, Merck, Merus, Mirati Therapeutics, NeoImmune Tech, Neovia Oncology, Novartis, Numab Therapeutics, Nuvalent, OncoMed Pharmaceuticals, Palleon Pharmaceuticals, Pfizer, PMV Pharmaceuticals, Rain Therapeutics, RasCal Therapeutics, Regeneron Pharmaceuticals, Relay Therapeutics, Revolution Medicines, Ribon Therapeutics, Rubius Therapeutics, Sanofi, Seven and Eight Biopharmaceuticals/Birdie Biopharmaceuticals, Shattuck Labs, Silicon Therapeutics, Stem CentRx, Syndax Pharmaceuticals, Takeda Pharmaceuticals, Tarveda, TCR2 Therapeutics, Tempest Therapeutics, Tizona Therapeutics, TMUNITY Therapeutics, Turning Point Therapeutics, University of Michigan, Vyriad, Y-mAbs Therapeutics. Ira Winer: Advisory board, Merck, GOG partners; Research grant, Oncoceutics. Hendrik-Tobias Arkenau declares no potential conflict of interest. Natalie Cook: Advisory council or committee, Roche, Cancer Research UK, RedX; Honoraria, Roche; Institutional research grants / funds: AstraZeneca, Orion, F. Hoffmann-La Roche Ltd, Taiho Pharmaceutical, GlaxoSmithKline, Novartis, Starpharma, Bayer, Eisai, UCB, Redx Pharmaceuticals, Stemline Therapeutics, Boehringer Ingelheim, Merck, AstraZeneca, Cancer Research UK. Vanessa Samouëlian: Consulting fee, Merck, GlaxoSmithKline. Raid Aljumaily declares no potential conflict of interest. Shigehisa Kitano: Honoraria: AstraZeneca, Pfizer, Regeneron Pharmaceuticals, Boehringer Ingelheim, Taiho Pharmaceutical, Novartis, MSD, Sumitomo Pharma, Eisai, Ono Pharmaceutical Co., Ltd., Bristol-Myers Squibb, Rakuten Medical, GlaxoSmithKline, Chugai, Merck Biopharma Co., Ltd, Takeda Pharmaceuticals; Consulting fee: ImmuniT Research Inc., United Immunity Co., Ltd.; Grants/Funds: Boehringer Ingelheim, Astellas, Gilead Sciences, Regeneron Pharmaceuticals, PACT Pharma, MSD, Eisai, Ono Pharmaceutical Co., Ltd., Takara Bio Inc., Daiichi-Sankyo, Chugai, AstraZeneca, Pfizer, Incyte, Takeda Pharmaceuticals. Christine Duffy: Employment, Boehringer Ingelheim. Miaomiao Ge: Employment, Boehringer Ingelheim. Mabrouk Elgadi: Employment, Boehringer Ingelheim. Lillian Siu: Ownership of stock/shares, Agios (spouse); Scientific Advisory Board/Consultancy (self), Merck, Pfizer, AstraZeneca, Roche, Symphogen, GlaxoSmithKline, Voronoi, Arvinas, Tessa, Navire, Relay, Janpix, Daiichi Sankyo, Coherus, Amgen, Marengo, InteRNA, Medicenna; Grants/Funds (institution, to conduct clinical trials), Novartis, Bristol-Myers Squibb, Pfizer, Boehringer-Ingelheim, GlaxoSmithKline, Roche/Genentech, Karyopharm, AstraZeneca, Merck, Celgene, Astellas, Bayer, Abbvie, Amgen, Symphogen, Intensity Therapeutics, Mirati Therapeutics, Shattucks Lab; Other, cofounder of Treadwell Therapeutics (spouse).
: The studies were conducted in accordance with the Declaration of Helsinki and Good Clinical Practice Guidelines. All patients provided written informed consent.